|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this work, we attempt to discuss some of the most recent molecular, preclinical and clinical evidence to construct a more exhaustive model of function for the BRAF V600E in development, progression and therapeutic approach of thyroid cancer.
|
24828987 |
2015 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we show that depletion of RAF-1, a RAF family member with a poorly defined role in TC, decreases proliferation and increases apoptosis in TPC-1 cells and, less significantly, in cells harboring a BRAF(V600E) or HRAS(G13R) mutations, but without affecting ERK activation.
|
26265449 |
2015 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.
|
24927793 |
2014 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutational status in pediatric thyroid cancer.
|
24677749 |
2014 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
|
24617711 |
2014 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall, BRAF(V600E) PTC tumors display a broadly immunosuppressive profile and evidence of disturbed host tumor immune surveillance that may contribute to the poorer outcomes observed in this subset of patients with thyroid cancer.
|
24955518 |
2014 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation and DNA methylation are useful markers to distinguish mali</span>gnant thyroid neoplasm from benign.
|
24588959 |
2014 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
The most common BRAF mutation in thyroid cancer is c.1799T>A (p.Val600Glu), and other BRAF mutations are rarely reported.
|
25120313 |
2014 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
PCCl3 rat thyroid cells, PCCl3 cells overexpressing BRAF(V600E), or primary cultured tumor cells from a thyroid cancer mouse model, under TSH stimulation were treated with various reagents for 24 hours.
|
24400871 |
2014 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation is the most common genetic alteration in thyroid cancer.
|
25266729 |
2014 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study investigates the expression of CYP24A1 and the effect of BRAF(V600E) on its expression in thyroid cancer.
|
24382015 |
2014 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings not only reveal an epigenetic mechanism for BRAF V600E-promoted NIS silencing involving histone deacetylation at critical regulatory regions of the NIS promoter but also provide further support for our previously proposed combination therapy targeting major signaling pathways and histone deacetylase to restore thyroid gene expression for radioiodine treatment of thyroid cancer.
|
24243688 |
2014 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
According to our experimental results, the panel including cf-DNA, SLC5A8 and SLC26A4 hypermethylation, and BRAF(V600E) analysis appears easy, reproducible, and non-invasive for the diagnosis on TC.
|
23931930 |
2013 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Second, homogeneous staining occurs in the vast majority of cases, demonstrating that the BRAF(T1799A) mutation is a clonal event in thyroid cancer.
|
23775351 |
2013 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
When BRAF(V600E)-positive thyroid cancer cells were incubated with the specific BRAF inhibitor PLX4032, sensitivity to gefitinib was restored.
|
23559083 |
2013 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results reveal a novel (V600E)BRAF-induced mechanism in thyroid tumours progression and provides a rationale for using the PLX4720 inhibitor to target (V600E)BRAF signalling to effectively control progression of thyroid cancer.
|
23435375 |
2013 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation can be detected peripherally in the serum of patients with thyroid cancer.
|
23161556 |
2013 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study tests the prevalence of BRAF (V600E) mutation in thyroid cancer patients in Indian subcontinental population.
|
22105775 |
2012 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
From September 2008 to December 2009, we performed routine analysis of the BRAF(V600E) mutation using thyroid cancer tissue from 424 patients who underwent thyroidectomy with cervical lymph node dissection.
|
21803329 |
2012 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
The diagnostic sensitivity for thyroid cancer is significantly increased by BRAF V600E mutation analysis, indicating that the screening for BRAF mutation in FNAB samples has a relevant diagnostic potential.
|
22535974 |
2012 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(T1799A) mutation is the most prevalent genetic alteration in thyroid cancers and is specific for PTC, characteristics that make it the most potentially helpful genetic tool to improve the diagnostic accuracy of FNAB.
|
22504197 |
2012 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Notch functions as an oncogene or tumor suppressor according to the type of malignancy, and the BRAF(V600E) mutation is commonly observed in thyroid cancer.
|
22118425 |
2012 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
It is evident that the detection of the BRAF V600E mutation is crucial in order to identify novel avenues for thyroid cancer treatment.
|
22858857 |
2012 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) ovarian cancers, 4/72 (5.5%) colorectal cancers, 1/355 (0.3%) lung cancers, 2/6 thyroid cancers and 1/2 choriocarcinomas.
|
22012135 |
2012 |